Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option...
Saved in:
| Published in | The Lancet infectious diseases Vol. 18; no. 1; pp. 47 - 57 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Ltd
01.01.2018
Elsevier B.V Elsevier Limited Elsevier Science ;, The Lancet Pub. Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1473-3099 1474-4457 1474-4457 |
| DOI | 10.1016/S1473-3099(17)30630-8 |
Cover
| Abstract | Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.
We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787.
Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification.
Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings.
European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. |
|---|---|
| AbstractList | Funding European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.BACKGROUNDMillions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings.We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787.METHODSWe analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787.Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification.FINDINGSBetween April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification.Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings.INTERPRETATIONProtease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings.European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO.FUNDINGEuropean and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings. We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787. Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification. Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings. European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. Summary Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings. Methods We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787. Findings Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification. Interpretation Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings. Funding European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. |
| Audience | Academic |
| Author | Tibyasa, M van Wyk, J Tuhirwe, S Labejja, P Ocitti Kayiwa, J Tanui, M Mulambo, S Ngonga, M Ninsiima, E Kendall, L Ndigendawan, M Namfukwe, M Mbidde, M Odong, W Alima, H Ssenkindu, T Tumwebaze, G Segonga, P Atukunda, F Acen, J Ekiru, W Lokitala Mugerwa, H Kasede, A Ishola, D Kerukadho, E Bakeinyaga, G Kityo, Cissy Odoi, M Owor Chikatula, E Cloherty, G Lwalanda, R Kafuma, S Mufwambi, W Nakajubi, A Rogers, A Mweemba, Aggrey Matama, C Namayanja Boles, J Ojoo, S Tuhirirwe, P Mbiya, R Senoga, I Awio, P Ssali, F Acaku, M Namusanje, J Mudoola, M Musowa, George Bekusike, G Katemba, C Kiconco, M Nsibuka, F Denis, O Moyo, C Palfreeman, A Mokaya, M Colebunders, R Balmoi, F Heyderman, Robert Achidri, J Komujuni, C Baliruno, D Kwobah, C Hakim, James G Easterbrook, Philippa Mushani, G Malik, K Odoch, D William, H Atwongyeire, D Wilkes, H Nalumenya, R Phiri, M Senyonjo, S Abiriga, R Lifa, Linly Arenas-Pinto, A Mugenyi, M Philliam, A Phiri, S Kambugu, Andrew Nambaziira, F Whittle, J Ditai, J Kyomugisha, H Abwola, M Kidega, P Katabaazi, J Mphande, T Okong, P Giuliano, M Namuyimbwa, L Okello, P N |
| AuthorAffiliation | e Department of Medicine, University of Malawi College of Medicine, Blantyre, Malawi h Moi University School of Medicine, Eldoret, Kenya i St Francis of Nsambya Hospital, Kampala, Uganda a University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe f Dignitas International, Zomba, Malawi k Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore c Joint Clinical Research Centre (JCRC) Kampala, Kampala, Uganda d Infectious Diseases Institute, Kampala, Uganda g JCRC Mbarara, Mbarara, Uganda b MRC Clinical Trials Unit at University College London, London, UK j University Teaching Hospital, Lusaka, Zambia |
| AuthorAffiliation_xml | – name: a University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe – name: c Joint Clinical Research Centre (JCRC) Kampala, Kampala, Uganda – name: g JCRC Mbarara, Mbarara, Uganda – name: e Department of Medicine, University of Malawi College of Medicine, Blantyre, Malawi – name: d Infectious Diseases Institute, Kampala, Uganda – name: b MRC Clinical Trials Unit at University College London, London, UK – name: h Moi University School of Medicine, Eldoret, Kenya – name: i St Francis of Nsambya Hospital, Kampala, Uganda – name: f Dignitas International, Zomba, Malawi – name: j University Teaching Hospital, Lusaka, Zambia – name: k Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore |
| Author_xml | – sequence: 2 givenname: Jennifer surname: Thompson fullname: Thompson, Jennifer organization: MRC Clinical Trials Unit at University College London, London, UK – sequence: 3 givenname: Cissy surname: Kityo fullname: Kityo, Cissy organization: Joint Clinical Research Centre (JCRC) Kampala, Kampala, Uganda – sequence: 5 givenname: Andrew surname: Kambugu fullname: Kambugu, Andrew organization: Infectious Diseases Institute, Kampala, Uganda – sequence: 7 givenname: Abbas surname: Lugemwa fullname: Lugemwa, Abbas organization: JCRC Mbarara, Mbarara, Uganda – sequence: 9 givenname: Raymond surname: Mwebaze fullname: Mwebaze, Raymond organization: St Francis of Nsambya Hospital, Kampala, Uganda – sequence: 12 givenname: Margaret J surname: Thomason fullname: Thomason, Margaret J organization: MRC Clinical Trials Unit at University College London, London, UK – sequence: 14 givenname: Peter surname: Mugyenyi fullname: Mugyenyi, Peter organization: Joint Clinical Research Centre (JCRC) Kampala, Kampala, Uganda – sequence: 15 givenname: A Sarah surname: Walker fullname: Walker, A Sarah organization: MRC Clinical Trials Unit at University College London, London, UK – sequence: 19 givenname: G surname: Bakeinyaga fullname: Bakeinyaga, G – sequence: 22 givenname: S surname: Kasuswa fullname: Kasuswa, S – sequence: 27 givenname: D surname: Mulima fullname: Mulima, D – sequence: 28 givenname: H surname: Musana fullname: Musana, H – sequence: 32 givenname: H surname: Namata fullname: Namata, H – sequence: 33 givenname: J surname: Nkalubo fullname: Nkalubo, J – sequence: 35 givenname: P surname: Okello fullname: Okello, P – sequence: 37 givenname: G surname: Pimundu fullname: Pimundu, G – sequence: 38 givenname: P surname: Segonga fullname: Segonga, P – sequence: 39 givenname: F surname: Ssali fullname: Ssali, F – sequence: 44 givenname: J surname: Kayiwa fullname: Kayiwa, J – sequence: 45 givenname: J surname: Tukamushaba fullname: Tukamushaba, J – sequence: 46 givenname: S surname: Abunyang fullname: Abunyang, S – sequence: 49 givenname: R surname: Lwalanda fullname: Lwalanda, R – sequence: 51 givenname: J surname: Namusanje fullname: Namusanje, J – sequence: 61 givenname: M surname: Katwere fullname: Katwere, M – sequence: 63 givenname: C surname: Komujuni fullname: Komujuni, C – sequence: 67 givenname: J surname: Matovu fullname: Matovu, J – sequence: 68 givenname: A surname: Nakajubi fullname: Nakajubi, A – sequence: 70 givenname: R surname: Nalumenya fullname: Nalumenya, R – sequence: 72 givenname: F surname: Semitala fullname: Semitala, F – sequence: 77 givenname: T surname: Ssenkindu fullname: Ssenkindu, T – sequence: 83 givenname: M surname: Acaku fullname: Acaku, M – sequence: 84 givenname: P surname: Ssebutinde fullname: Ssebutinde, P – sequence: 86 givenname: J surname: Kukundakwe fullname: Kukundakwe, J – sequence: 87 givenname: M surname: Naluguza fullname: Naluguza, M – sequence: 90 givenname: F surname: Nsibuka fullname: Nsibuka, F – sequence: 92 givenname: M surname: Fortunate fullname: Fortunate, M – sequence: 93 givenname: J surname: Acen fullname: Acen, J – sequence: 94 givenname: J surname: Achidri fullname: Achidri, J – sequence: 96 givenname: M surname: Chamai fullname: Chamai, M – sequence: 99 givenname: M surname: Kiconco fullname: Kiconco, M – sequence: 100 givenname: C surname: Matama fullname: Matama, C – sequence: 102 givenname: F surname: Nambaziira fullname: Nambaziira, F – sequence: 104 givenname: A surname: Rweyora fullname: Rweyora, A – sequence: 105 givenname: G surname: Tumwebaze fullname: Tumwebaze, G – sequence: 108 givenname: A surname: Kiyingi fullname: Kiyingi, A – sequence: 112 givenname: I surname: Senoga fullname: Senoga, I – sequence: 113 givenname: M surname: Abwola fullname: Abwola, M – sequence: 117 givenname: M surname: Mudoola fullname: Mudoola, M – sequence: 119 givenname: F surname: Ssennono fullname: Ssennono, F – sequence: 121 givenname: G surname: Amone fullname: Amone, G – sequence: 124 givenname: B surname: Arach fullname: Arach, B – sequence: 134 givenname: G surname: Bekusike fullname: Bekusike, G – sequence: 135 givenname: A surname: Bulegyeya fullname: Bulegyeya, A – sequence: 139 givenname: A surname: Nassali fullname: Nassali, A – sequence: 142 surname: Ndukukire fullname: Ndukukire – sequence: 144 givenname: H surname: Ntawiha fullname: Ntawiha, H – sequence: 145 givenname: A surname: Rogers fullname: Rogers, A – sequence: 147 givenname: S surname: Kiirya fullname: Kiirya, S – sequence: 157 givenname: F surname: Balmoi fullname: Balmoi, F – sequence: 158 givenname: S surname: Kafuma fullname: Kafuma, S – sequence: 166 givenname: M surname: Phiri fullname: Phiri, M – sequence: 167 givenname: S surname: Mudzingwa fullname: Mudzingwa, S – sequence: 168 givenname: T surname: Bafana fullname: Bafana, T – sequence: 172 givenname: S surname: Chitongo fullname: Chitongo, S – sequence: 177 givenname: Linly surname: Lifa fullname: Lifa, Linly – sequence: 181 givenname: George surname: Musowa fullname: Musowa, George – sequence: 182 givenname: Grace surname: Mwimaniwa fullname: Mwimaniwa, Grace – sequence: 183 givenname: Rosemary surname: Sikwese fullname: Sikwese, Rosemary – sequence: 184 givenname: Milton surname: Ziwoya fullname: Ziwoya, Milton – sequence: 186 givenname: S surname: Kamanga fullname: Kamanga, S – sequence: 187 givenname: T Kayinga E surname: Makwakwa fullname: Makwakwa, T Kayinga E – sequence: 189 givenname: M surname: Mlenga fullname: Mlenga, M – sequence: 190 givenname: T surname: Mphande fullname: Mphande, T – sequence: 191 givenname: C surname: Mtika fullname: Mtika, C – sequence: 196 givenname: R surname: Nyirenda fullname: Nyirenda, R – sequence: 201 givenname: A surname: Mudogo fullname: Mudogo, A – sequence: 205 givenname: K surname: Wools-Kaloustian fullname: Wools-Kaloustian, K – sequence: 209 givenname: I surname: Kunda fullname: Kunda, I – sequence: 212 givenname: W surname: Mufwambi fullname: Mufwambi, W – sequence: 213 givenname: L surname: Mulenga fullname: Mulenga, L – sequence: 216 givenname: M surname: Namfukwe fullname: Namfukwe, M – sequence: 217 givenname: E surname: Kerukadho fullname: Kerukadho, E – sequence: 218 givenname: B surname: Ngwatu fullname: Ngwatu, B – sequence: 225 givenname: S surname: Tebbs fullname: Tebbs, S – sequence: 226 givenname: J surname: Whittle fullname: Whittle, J – sequence: 227 givenname: H surname: Wilkes fullname: Wilkes, H – sequence: 231 givenname: F surname: Kyomuhendo fullname: Kyomuhendo, F – sequence: 233 givenname: N surname: Mkandawire fullname: Mkandawire, N – sequence: 235 givenname: S surname: Senyonjo fullname: Senyonjo, S – sequence: 236 givenname: B surname: Angus fullname: Angus, B – sequence: 238 givenname: A surname: Palfreeman fullname: Palfreeman, A – sequence: 241 givenname: J surname: Arribas fullname: Arribas, J – sequence: 243 givenname: M surname: Floridia fullname: Floridia, M – sequence: 246 givenname: P surname: Walsh fullname: Walsh, P – sequence: 247 givenname: M surname: De Rosa fullname: De Rosa, M – sequence: 250 givenname: C surname: Gilks fullname: Gilks, C – sequence: 251 givenname: A surname: Kangewende fullname: Kangewende, A – sequence: 261 givenname: J surname: van Wyk fullname: van Wyk, J – sequence: 263 givenname: S surname: Lehrman fullname: Lehrman, S – sequence: 266 givenname: J surname: Rooney fullname: Rooney, J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29108797$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9qFDEYxQep2D_6CEpAkBY6muxkJhNFpZTVFhYFW70Nmcw3u2kzyZhktvZVfRqz3VraXlivJuT7nTM5ydnONqyzkGXPCX5NMKnenBDKirzAnO8StlfgqsB5_SjbSts0p7RkG1frNbKZbYdwhjFhBNMn2eaEE1wzzray3zM3aCuX2qPBjAHZURlwQbeAPCzBB8ijlzYor4coAyBtF7rR0fmwj8xdrZcmwtyvNvaR87fGvbMuLsDL4RJ1aRJAOdvmRltA0YOMPdiIXIeOjn-g3enBty_Tk9O9t4hQml8AnCeRMe4iH4d0qjCaGFDnXY9k-qdtXa8DtChZRp-4tIxeS_M0e9xJE-DZ9Xcn-_5penp4lM--fj4-PJjlqsJ1zJsJkZjhQlacq6qYcC6BAkipOtKxpmk5haYqJK06VhPJKeF1W9Y1hZY3tGHFTvZh7TuMTQ-tSlHSTYjB6176S-GkFncnVi_E3C1FyQpeszIZ7F4bePdzhBBFCqTAGGnBjUEQXpGqqEtcJPTlPfTMjd6meGJCq5KRejLh_6LS4QtKGatool6tqbk0ILRd3R_8inM5hiDEQZnQsqZllcAXtwPeJPvbogSUa0B5F4KH7gYhWKzaKq7aKlZVFISJq7aKOune3dMpHWXUq4eU2jyo_rhWQ3rcpQYvgtJgFbTag4qidfpBh_f3HFSqpFbSnMPlf-j_ADCFG1Q |
| CitedBy_id | crossref_primary_10_3389_fphar_2018_00890 crossref_primary_10_1097_INF_0000000000003647 crossref_primary_10_1093_cid_ciad023 crossref_primary_10_1111_hiv_13252 crossref_primary_10_1146_annurev_pharmtox_052020_094321 crossref_primary_10_3390_diagnostics13132209 crossref_primary_10_1097_MD_0000000000021661 crossref_primary_10_1093_cid_ciy589 crossref_primary_10_12688_wellcomeopenres_16597_1 crossref_primary_10_1002_phar_2246 crossref_primary_10_1097_QAD_0000000000002936 crossref_primary_10_1097_QAD_0000000000002958 crossref_primary_10_1080_25787489_2022_2103572 crossref_primary_10_1111_hiv_12636 crossref_primary_10_4102_sajhivmed_v24i1_1536 crossref_primary_10_3389_fphar_2019_01225 crossref_primary_10_7326_M21_2229 crossref_primary_10_1056_NEJMoa2101609 crossref_primary_10_1016_S2352_3018_21_00268_X crossref_primary_10_1002_jia2_26315 crossref_primary_10_1097_QAD_0000000000003108 crossref_primary_10_1111_tmi_13131 crossref_primary_10_1016_j_jclinepi_2022_02_005 crossref_primary_10_1080_15548627_2024_2325304 crossref_primary_10_1093_cid_ciaa1161 crossref_primary_10_1093_jac_dkab025 crossref_primary_10_1016_j_jcv_2020_104547 crossref_primary_10_1186_s12879_018_3489_7 crossref_primary_10_1097_QAD_0000000000003488 crossref_primary_10_4102_sajhivmed_v23i1_1428 crossref_primary_10_1371_journal_pone_0227600 crossref_primary_10_1089_aid_2019_0232 crossref_primary_10_1097_MD_0000000000020516 crossref_primary_10_1177_2049936120901395 |
| Cites_doi | 10.1097/QAD.0000000000000709 10.1016/S0140-6736(06)69158-7 10.1186/s12981-016-0113-z 10.1097/QAI.0000000000000898 10.1097/QAI.0000000000001285 10.1097/01.qai.0000167155.44980.e8 10.3851/IMP1832 10.1056/NEJMoa1311274 10.1007/s13365-015-0374-7 10.1111/hiv.12426 10.1371/journal.pone.0118228 10.1310/hct1205-255 10.1089/aid.2011.0275 10.1016/S2352-3018(17)30065-6 10.2165/11633630-000000000-00000 10.1310/hct1104-205 10.1016/S0140-6736(14)61170-3 10.1016/S2352-3018(16)00024-2 10.1093/jac/dkv176 10.1016/S2352-3018(16)30011-X 10.1128/AAC.00593-11 10.2174/1574884711666160329192333 |
| ContentType | Journal Article |
| Contributor | Buluma, E Kalanzi, H Kiyingi, A Labejja, P Ocitti Kayiwa, J Rweyora, A Ninsiima, E Ndigendawan, M Mbidde, M Ssenkindu, T Tumwebaze, G Segonga, P Fortunate, M Atwine, L Nabulime, E Acen, J Matovu, J Mugerwa, H Kasede, A Bakeinyaga, G Odoi, M Owor Senfuma, O Nakku, J Lubwama, E Chamai, M Lwalanda, R Nakajubi, A Namala, W Mugarura, L Matama, C Namayanja Tuhirirwe, P Senoga, I Awio, P Ssali, F Tumukunde, D Acaku, M Namusanje, J Katemba, C Ssegawa, K Musitwa, G Bihabwa, G Kiggundu, R Kiconco, M Agweng, E Nsibuka, F Denis, O Tamale, Z Achidri, J Komujuni, C Baliruno, D Katuramu, M Ndashimye, E William, H Olal, P Nalumenya, R Kemigisa, M Mugenyi, M Kabuga, U Nambaziira, F Ditai, J Kyomugisha, H Amone, A Abwola, M Katabaazi, J Okong, P Namuyimbwa, L Okello, P Semitala, F Kitizo, H Laker, E Pimundu, G Mambule, I Musana, H Namata, H Tukamushaba, J Isabirye, C Elbireer, A Musiime, V Kukundakwe, J Kasuswa, S Wanyama, J Lutalo, E Kiweewa, F Abunyang, S Eram, D Mwebe, S Mulima, D Nkalubo, J Katwere, M Nankya, I Ssebutinde, P Byaruhanga, R Mbanza, D Wandera, B Kamya, D Bwomezi, J Naluguza, M |
| Contributor_xml | – sequence: 1 givenname: E surname: Agweng fullname: Agweng, E – sequence: 2 givenname: P surname: Awio fullname: Awio, P – sequence: 3 givenname: G surname: Bakeinyaga fullname: Bakeinyaga, G – sequence: 4 givenname: C surname: Isabirye fullname: Isabirye, C – sequence: 5 givenname: U surname: Kabuga fullname: Kabuga, U – sequence: 6 givenname: S surname: Kasuswa fullname: Kasuswa, S – sequence: 7 givenname: M surname: Katuramu fullname: Katuramu, M – sequence: 8 givenname: F surname: Kiweewa fullname: Kiweewa, F – sequence: 9 givenname: H surname: Kyomugisha fullname: Kyomugisha, H – sequence: 10 givenname: E surname: Lutalo fullname: Lutalo, E – sequence: 11 givenname: D surname: Mulima fullname: Mulima, D – sequence: 12 givenname: H surname: Musana fullname: Musana, H – sequence: 13 givenname: G surname: Musitwa fullname: Musitwa, G – sequence: 14 givenname: V surname: Musiime fullname: Musiime, V – sequence: 15 givenname: M surname: Ndigendawan fullname: Ndigendawan, M – sequence: 16 givenname: H surname: Namata fullname: Namata, H – sequence: 17 givenname: J surname: Nkalubo fullname: Nkalubo, J – sequence: 18 givenname: P Ocitti surname: Labejja fullname: Labejja, P Ocitti – sequence: 19 givenname: P surname: Okello fullname: Okello, P – sequence: 20 givenname: P surname: Olal fullname: Olal, P – sequence: 21 givenname: G surname: Pimundu fullname: Pimundu, G – sequence: 22 givenname: P surname: Segonga fullname: Segonga, P – sequence: 23 givenname: F surname: Ssali fullname: Ssali, F – sequence: 24 givenname: Z surname: Tamale fullname: Tamale, Z – sequence: 25 givenname: D surname: Tumukunde fullname: Tumukunde, D – sequence: 26 givenname: W surname: Namala fullname: Namala, W – sequence: 27 givenname: R surname: Byaruhanga fullname: Byaruhanga, R – sequence: 28 givenname: J surname: Kayiwa fullname: Kayiwa, J – sequence: 29 givenname: J surname: Tukamushaba fullname: Tukamushaba, J – sequence: 30 givenname: S surname: Abunyang fullname: Abunyang, S – sequence: 31 givenname: D surname: Eram fullname: Eram, D – sequence: 32 givenname: O surname: Denis fullname: Denis, O – sequence: 33 givenname: R surname: Lwalanda fullname: Lwalanda, R – sequence: 34 givenname: L surname: Mugarura fullname: Mugarura, L – sequence: 35 givenname: J surname: Namusanje fullname: Namusanje, J – sequence: 36 givenname: I surname: Nankya fullname: Nankya, I – sequence: 37 givenname: E surname: Ndashimye fullname: Ndashimye, E – sequence: 38 givenname: E surname: Nabulime fullname: Nabulime, E – sequence: 39 givenname: O surname: Senfuma fullname: Senfuma, O – sequence: 40 givenname: G surname: Bihabwa fullname: Bihabwa, G – sequence: 41 givenname: E surname: Buluma fullname: Buluma, E – sequence: 42 givenname: A surname: Elbireer fullname: Elbireer, A – sequence: 43 givenname: D surname: Kamya fullname: Kamya, D – sequence: 44 givenname: M surname: Katwere fullname: Katwere, M – sequence: 45 givenname: R surname: Kiggundu fullname: Kiggundu, R – sequence: 46 givenname: C surname: Komujuni fullname: Komujuni, C – sequence: 47 givenname: E surname: Laker fullname: Laker, E – sequence: 48 givenname: E surname: Lubwama fullname: Lubwama, E – sequence: 49 givenname: I surname: Mambule fullname: Mambule, I – sequence: 50 givenname: J surname: Matovu fullname: Matovu, J – sequence: 51 givenname: A surname: Nakajubi fullname: Nakajubi, A – sequence: 52 givenname: J surname: Nakku fullname: Nakku, J – sequence: 53 givenname: R surname: Nalumenya fullname: Nalumenya, R – sequence: 54 givenname: L surname: Namuyimbwa fullname: Namuyimbwa, L – sequence: 55 givenname: F surname: Semitala fullname: Semitala, F – sequence: 56 givenname: B surname: Wandera fullname: Wandera, B – sequence: 57 givenname: J surname: Wanyama fullname: Wanyama, J – sequence: 58 givenname: H surname: Mugerwa fullname: Mugerwa, H – sequence: 59 givenname: E surname: Ninsiima fullname: Ninsiima, E – sequence: 60 givenname: T surname: Ssenkindu fullname: Ssenkindu, T – sequence: 61 givenname: S surname: Mwebe fullname: Mwebe, S – sequence: 62 givenname: L surname: Atwine fullname: Atwine, L – sequence: 63 givenname: H surname: William fullname: William, H – sequence: 64 givenname: C surname: Katemba fullname: Katemba, C – sequence: 65 givenname: M surname: Acaku fullname: Acaku, M – sequence: 66 givenname: P surname: Ssebutinde fullname: Ssebutinde, P – sequence: 67 givenname: H surname: Kitizo fullname: Kitizo, H – sequence: 68 givenname: J surname: Kukundakwe fullname: Kukundakwe, J – sequence: 69 givenname: M surname: Naluguza fullname: Naluguza, M – sequence: 70 givenname: K surname: Ssegawa fullname: Ssegawa, K – sequence: 71 surname: Namayanja fullname: Namayanja – sequence: 72 givenname: F surname: Nsibuka fullname: Nsibuka, F – sequence: 73 givenname: P surname: Tuhirirwe fullname: Tuhirirwe, P – sequence: 74 givenname: M surname: Fortunate fullname: Fortunate, M – sequence: 75 givenname: J surname: Acen fullname: Acen, J – sequence: 76 givenname: J surname: Achidri fullname: Achidri, J – sequence: 77 givenname: A surname: Amone fullname: Amone, A – sequence: 78 givenname: M surname: Chamai fullname: Chamai, M – sequence: 79 givenname: J surname: Ditai fullname: Ditai, J – sequence: 80 givenname: M surname: Kemigisa fullname: Kemigisa, M – sequence: 81 givenname: M surname: Kiconco fullname: Kiconco, M – sequence: 82 givenname: C surname: Matama fullname: Matama, C – sequence: 83 givenname: D surname: Mbanza fullname: Mbanza, D – sequence: 84 givenname: F surname: Nambaziira fullname: Nambaziira, F – sequence: 85 givenname: M Owor surname: Odoi fullname: Odoi, M Owor – sequence: 86 givenname: A surname: Rweyora fullname: Rweyora, A – sequence: 87 givenname: G surname: Tumwebaze fullname: Tumwebaze, G – sequence: 88 givenname: H surname: Kalanzi fullname: Kalanzi, H – sequence: 89 givenname: J surname: Katabaazi fullname: Katabaazi, J – sequence: 90 givenname: A surname: Kiyingi fullname: Kiyingi, A – sequence: 91 givenname: M surname: Mbidde fullname: Mbidde, M – sequence: 92 givenname: M surname: Mugenyi fullname: Mugenyi, M – sequence: 93 givenname: P surname: Okong fullname: Okong, P – sequence: 94 givenname: I surname: Senoga fullname: Senoga, I – sequence: 95 givenname: M surname: Abwola fullname: Abwola, M – sequence: 96 givenname: D surname: Baliruno fullname: Baliruno, D – sequence: 97 givenname: J surname: Bwomezi fullname: Bwomezi, J – sequence: 98 givenname: A surname: Kasede fullname: Kasede, A |
| Copyright | 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Jan 1, 2018 2018. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018 |
| Copyright_xml | – notice: 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Jan 1, 2018 – notice: 2018. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018 |
| CorporateAuthor | Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team |
| CorporateAuthor_xml | – name: Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1016/S1473-3099(17)30630-8 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Pharma and Biotech Premium PRO MEDLINE - Academic MEDLINE Pharma and Biotech Premium PRO |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | 57 |
| ExternalDocumentID | PMC5739875 A519858456 29108797 10_1016_S1473_3099_17_30630_8 S1473309917306308 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Africa South of the Sahara Malawi Africa Uganda Kampala Uganda |
| GeographicLocations_xml | – name: Africa South of the Sahara – name: Africa – name: Malawi – name: Uganda – name: Kampala Uganda |
| GrantInformation | European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO. |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_12023/23 – fundername: NIAID NIH HHS grantid: U01 AI069911 |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R 3V. 6I. AACTN AAFTH AAYOK ABLVK ABYKQ AFKWA AJBFU AJOXV AMFUW RIG SDF ZA5 AAYXX AFCTW AGRNS ALIPV CITATION CGR CUY CVF ECM EIF NPM 0TZ 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI 7X8 ACLOT ~HD 5PM |
| ID | FETCH-LOGICAL-c608t-b21a0703a699c63299ae4eeaacf1f7bbd94eb63a46f781a94198d5884ed9b4b73 |
| IEDL.DBID | 7X7 |
| ISSN | 1473-3099 1474-4457 |
| IngestDate | Thu Aug 21 14:01:44 EDT 2025 Sun Sep 28 03:00:35 EDT 2025 Sat Jul 26 00:08:11 EDT 2025 Sat Jul 26 00:16:50 EDT 2025 Fri Jun 27 05:29:43 EDT 2025 Mon Jul 21 06:04:07 EDT 2025 Tue Jul 01 01:42:53 EDT 2025 Thu Apr 24 22:55:20 EDT 2025 Fri Feb 23 02:47:13 EST 2024 Tue Aug 26 17:35:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c608t-b21a0703a699c63299ae4eeaacf1f7bbd94eb63a46f781a94198d5884ed9b4b73 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Members listed in the appendix Contributed equally |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5739875 |
| PMID | 29108797 |
| PQID | 1983447764 |
| PQPubID | 44001 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5739875 proquest_miscellaneous_1961638503 proquest_journals_2465718229 proquest_journals_1983447764 gale_incontextgauss__A519858456 pubmed_primary_29108797 crossref_primary_10_1016_S1473_3099_17_30630_8 crossref_citationtrail_10_1016_S1473_3099_17_30630_8 elsevier_sciencedirect_doi_10_1016_S1473_3099_17_30630_8 elsevier_clinicalkey_doi_10_1016_S1473_3099_17_30630_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2018 2018-01-00 20180101 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: January 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2018 |
| Publisher | Elsevier Ltd Elsevier B.V Elsevier Limited Elsevier Science ;, The Lancet Pub. Group |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier B.V – name: Elsevier Limited – name: Elsevier Science ;, The Lancet Pub. Group |
| References | La Rosa, Harrison, Taiwo (bib5) 2016; 3 Tang, Shafer (bib22) 2012; 72 bib12 Kambugu, Thompson, Hakim (bib7) 2016; 71 Salome, Kasamba, Mayanja (bib17) 2016; 13 Amin, Boyd, Kumarasamy (bib4) 2015; 10 Gallant, Daar, Raffi (bib18) 2016; 3 Raffi, Babiker, Richert (bib25) 2014; 384 (bib8) Aug 7, 2006 Paton, Kityo, Thompson (bib15) 2017; 4 Paton, Kityo, Hoppe (bib3) 2014; 371 Kityo, Thompson, Nankya (bib14) 2017; 75 (bib2) 2016 Reynes, Trinh, Pulido (bib24) 2013; 29 Ciaffi, Koulla-Shiro, Sawadogo (bib19) 2015; 29 Osman, Mesplede, Quashie, Oliveira, Zanichelli, Wainberg (bib27) 2015; 70 Hawkins, Veikley, St Claire, Guyer, Clark, Kearney (bib20) 2005; 39 Lifson, Belloso, Davey (bib9) 2010; 11 Singh, Kaur, Kumar, Kumar (bib26) 2016; 11 Wang, Soon, Seng (bib21) 2011; 55 Arenas-Pinto, Thompson, Musoro (bib6) 2016; 22 Reynes, Lawal, Pulido (bib23) 2011; 12 (bib11) October, 2015 Gilks, Crowley, Ekpini (bib1) 2006; 368 Aboud, Kaplan, Lombard (bib28) 2017 Stohr, Reid, Walker (bib16) 2011; 16 (bib10) 2004 Churchill, Waters, Ahmed (bib13) 2016; 17 (10.1016/S1473-3099(17)30630-8_bib2) 2016 (10.1016/S1473-3099(17)30630-8_bib8) 2006 Aboud (10.1016/S1473-3099(17)30630-8_bib28) 2017 Osman (10.1016/S1473-3099(17)30630-8_bib27) 2015; 70 Ciaffi (10.1016/S1473-3099(17)30630-8_bib19) 2015; 29 Kambugu (10.1016/S1473-3099(17)30630-8_bib7) 2016; 71 Stohr (10.1016/S1473-3099(17)30630-8_bib16) 2011; 16 Raffi (10.1016/S1473-3099(17)30630-8_bib25) 2014; 384 Churchill (10.1016/S1473-3099(17)30630-8_bib13) 2016; 17 Amin (10.1016/S1473-3099(17)30630-8_bib4) 2015; 10 Salome (10.1016/S1473-3099(17)30630-8_bib17) 2016; 13 Reynes (10.1016/S1473-3099(17)30630-8_bib24) 2013; 29 Hawkins (10.1016/S1473-3099(17)30630-8_bib20) 2005; 39 Reynes (10.1016/S1473-3099(17)30630-8_bib23) 2011; 12 Lifson (10.1016/S1473-3099(17)30630-8_bib9) 2010; 11 Paton (10.1016/S1473-3099(17)30630-8_bib15) 2017; 4 Tang (10.1016/S1473-3099(17)30630-8_bib22) 2012; 72 Arenas-Pinto (10.1016/S1473-3099(17)30630-8_bib6) 2016; 22 Gallant (10.1016/S1473-3099(17)30630-8_bib18) 2016; 3 La Rosa (10.1016/S1473-3099(17)30630-8_bib5) 2016; 3 Gilks (10.1016/S1473-3099(17)30630-8_bib1) 2006; 368 (10.1016/S1473-3099(17)30630-8_bib11) 2015 Singh (10.1016/S1473-3099(17)30630-8_bib26) 2016; 11 Paton (10.1016/S1473-3099(17)30630-8_bib3) 2014; 371 (10.1016/S1473-3099(17)30630-8_bib10) 2004 Wang (10.1016/S1473-3099(17)30630-8_bib21) 2011; 55 Kityo (10.1016/S1473-3099(17)30630-8_bib14) 2017; 75 29108798 - Lancet Infect Dis. 2018 Jan;18(1):3-5. doi: 10.1016/S1473-3099(17)30631-X. |
| References_xml | – year: 2004 ident: bib10 article-title: Division of AIDS table for grading the severity of adverse events – volume: 11 start-page: 88 year: 2016 end-page: 94 ident: bib26 article-title: The promise of dolutegravir: a novel second generation integrase strand transfer inhibitor publication-title: Curr Clin Pharmacol – volume: 12 start-page: 255 year: 2011 end-page: 267 ident: bib23 article-title: Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results publication-title: HIV Clin Trials – year: 2016 ident: bib2 article-title: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – volume: 13 start-page: 28 year: 2016 ident: bib17 article-title: The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis publication-title: AIDS Res Ther – volume: 10 start-page: e0118228 year: 2015 ident: bib4 article-title: Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection publication-title: PLoS One – volume: 11 start-page: 205 year: 2010 end-page: 219 ident: bib9 article-title: Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials publication-title: HIV Clin Trial – year: Aug 7, 2006 ident: bib8 article-title: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children – volume: 55 start-page: 4090 year: 2011 end-page: 4095 ident: bib21 article-title: Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers publication-title: Antimicrob Agents Chemother – volume: 371 start-page: 234 year: 2014 end-page: 247 ident: bib3 article-title: Assessment of second-line antiretroviral regimens for HIV therapy in Africa publication-title: N Engl J Med – volume: 3 start-page: e247 year: 2016 end-page: e258 ident: bib5 article-title: Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study publication-title: Lancet HIV – volume: 4 start-page: e341 year: 2017 end-page: e348 ident: bib15 article-title: Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial publication-title: Lancet HIV – year: October, 2015 ident: bib11 article-title: Guidelines 8.0 – volume: 368 start-page: 505 year: 2006 end-page: 510 ident: bib1 article-title: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings publication-title: Lancet – volume: 22 start-page: 104 year: 2016 end-page: 113 ident: bib6 article-title: Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial publication-title: J Neurovirol – volume: 71 start-page: 506 year: 2016 end-page: 513 ident: bib7 article-title: Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: analyses from the EARNEST trial publication-title: J Acquir Immune Defic Syndr – volume: 70 start-page: 2810 year: 2015 end-page: 2815 ident: bib27 article-title: Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout publication-title: J Antimicrob Chemother – ident: bib12 article-title: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents – start-page: 5613 year: 2017 ident: bib28 article-title: Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir plus ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study publication-title: 9th IAS Conference 2017 – volume: 29 start-page: 256 year: 2013 end-page: 265 ident: bib24 article-title: Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study publication-title: AIDS Res Hum Retroviruses – volume: 384 start-page: 1942 year: 2014 end-page: 1951 ident: bib25 article-title: Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial publication-title: Lancet – volume: 3 start-page: e158 year: 2016 end-page: e165 ident: bib18 article-title: Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial publication-title: Lancet HIV – volume: 39 start-page: 406 year: 2005 end-page: 411 ident: bib20 article-title: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens publication-title: J Acquir Immune Defic Syndr – volume: 16 start-page: 1011 year: 2011 end-page: 1020 ident: bib16 article-title: Glomerular dysfunction and associated risk factors over 4–5 years following antiretroviral therapy initiation in Africa publication-title: Antivir Ther – volume: 29 start-page: 1473 year: 2015 end-page: 1481 ident: bib19 article-title: Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa publication-title: AIDS – volume: 75 start-page: e45 year: 2017 end-page: e54 ident: bib14 article-title: HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa publication-title: J Acquir Immune Defic Syndr – volume: 17 start-page: s2 year: 2016 end-page: s104 ident: bib13 article-title: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 publication-title: HIV Med – volume: 72 start-page: e1 year: 2012 end-page: e25 ident: bib22 article-title: HIV-1 antiretroviral resistance: scientific principles and clinical applications publication-title: Drugs – year: 2006 ident: 10.1016/S1473-3099(17)30630-8_bib8 – volume: 29 start-page: 1473 year: 2015 ident: 10.1016/S1473-3099(17)30630-8_bib19 article-title: Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa publication-title: AIDS doi: 10.1097/QAD.0000000000000709 – volume: 368 start-page: 505 year: 2006 ident: 10.1016/S1473-3099(17)30630-8_bib1 article-title: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings publication-title: Lancet doi: 10.1016/S0140-6736(06)69158-7 – volume: 13 start-page: 28 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib17 article-title: The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis publication-title: AIDS Res Ther doi: 10.1186/s12981-016-0113-z – year: 2015 ident: 10.1016/S1473-3099(17)30630-8_bib11 – volume: 71 start-page: 506 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib7 article-title: Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: analyses from the EARNEST trial publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000000898 – volume: 75 start-page: e45 year: 2017 ident: 10.1016/S1473-3099(17)30630-8_bib14 article-title: HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000001285 – volume: 39 start-page: 406 year: 2005 ident: 10.1016/S1473-3099(17)30630-8_bib20 article-title: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000167155.44980.e8 – volume: 16 start-page: 1011 year: 2011 ident: 10.1016/S1473-3099(17)30630-8_bib16 article-title: Glomerular dysfunction and associated risk factors over 4–5 years following antiretroviral therapy initiation in Africa publication-title: Antivir Ther doi: 10.3851/IMP1832 – volume: 371 start-page: 234 year: 2014 ident: 10.1016/S1473-3099(17)30630-8_bib3 article-title: Assessment of second-line antiretroviral regimens for HIV therapy in Africa publication-title: N Engl J Med doi: 10.1056/NEJMoa1311274 – volume: 22 start-page: 104 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib6 article-title: Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial publication-title: J Neurovirol doi: 10.1007/s13365-015-0374-7 – volume: 17 start-page: s2 issue: suppl 4 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib13 article-title: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 publication-title: HIV Med doi: 10.1111/hiv.12426 – start-page: 5613 year: 2017 ident: 10.1016/S1473-3099(17)30630-8_bib28 article-title: Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir plus ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study – volume: 10 start-page: e0118228 year: 2015 ident: 10.1016/S1473-3099(17)30630-8_bib4 article-title: Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection publication-title: PLoS One doi: 10.1371/journal.pone.0118228 – year: 2004 ident: 10.1016/S1473-3099(17)30630-8_bib10 – volume: 12 start-page: 255 year: 2011 ident: 10.1016/S1473-3099(17)30630-8_bib23 article-title: Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results publication-title: HIV Clin Trials doi: 10.1310/hct1205-255 – year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib2 – volume: 29 start-page: 256 year: 2013 ident: 10.1016/S1473-3099(17)30630-8_bib24 article-title: Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2011.0275 – volume: 4 start-page: e341 year: 2017 ident: 10.1016/S1473-3099(17)30630-8_bib15 article-title: Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial publication-title: Lancet HIV doi: 10.1016/S2352-3018(17)30065-6 – volume: 72 start-page: e1 year: 2012 ident: 10.1016/S1473-3099(17)30630-8_bib22 article-title: HIV-1 antiretroviral resistance: scientific principles and clinical applications publication-title: Drugs doi: 10.2165/11633630-000000000-00000 – volume: 11 start-page: 205 year: 2010 ident: 10.1016/S1473-3099(17)30630-8_bib9 article-title: Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials publication-title: HIV Clin Trial doi: 10.1310/hct1104-205 – volume: 384 start-page: 1942 year: 2014 ident: 10.1016/S1473-3099(17)30630-8_bib25 article-title: Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61170-3 – volume: 3 start-page: e158 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib18 publication-title: Lancet HIV doi: 10.1016/S2352-3018(16)00024-2 – volume: 70 start-page: 2810 year: 2015 ident: 10.1016/S1473-3099(17)30630-8_bib27 article-title: Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv176 – volume: 3 start-page: e247 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib5 article-title: Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study publication-title: Lancet HIV doi: 10.1016/S2352-3018(16)30011-X – volume: 55 start-page: 4090 year: 2011 ident: 10.1016/S1473-3099(17)30630-8_bib21 article-title: Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00593-11 – volume: 11 start-page: 88 year: 2016 ident: 10.1016/S1473-3099(17)30630-8_bib26 article-title: The promise of dolutegravir: a novel second generation integrase strand transfer inhibitor publication-title: Curr Clin Pharmacol doi: 10.2174/1574884711666160329192333 – reference: 29108798 - Lancet Infect Dis. 2018 Jan;18(1):3-5. doi: 10.1016/S1473-3099(17)30631-X. |
| SSID | ssj0017104 |
| Score | 2.4169183 |
| Snippet | Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines... Funding European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish... Summary Background Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens.... |
| SourceID | pubmedcentral proquest gale pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 47 |
| SubjectTerms | Acquired immune deficiency syndrome Adolescent Adolescents Adult Africa South of the Sahara Aged AIDS Analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiretroviral Therapy, Highly Active - adverse effects Antiretroviral Therapy, Highly Active - methods Breastfeeding & lactation Care and treatment Child Clinical trials Confidence limits Developing countries Drug therapy Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Follow-Up Studies Health services HIV HIV (Viruses) HIV Infections - drug therapy Human immunodeficiency virus Humans Immunology Infectious diseases Laboratories LDCs Lopinavir Lopinavir - administration & dosage Lopinavir - adverse effects Male Medical research Middle Aged Nucleosides Patients Protease Protease inhibitors Proteases Proteinase inhibitors Public health Raltegravir Raltegravir Potassium - administration & dosage Raltegravir Potassium - adverse effects Randomization Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - adverse effects Ritonavir Ritonavir - administration & dosage Ritonavir - adverse effects Treatment Outcome Viral Load Young Adult |
| Title | Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1473309917306308 https://dx.doi.org/10.1016/S1473-3099(17)30630-8 https://www.ncbi.nlm.nih.gov/pubmed/29108797 https://www.proquest.com/docview/1983447764 https://www.proquest.com/docview/2465718229 https://www.proquest.com/docview/1961638503 https://pubmed.ncbi.nlm.nih.gov/PMC5739875 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9RAFB60BRFEtN6itY7gQwsdu9lM5uKLrGXLKnaRXmTfhlwmNhiSNdlY_Kv-Gs9JsumuqPUlhJw92ZCc-c43M-dCyKuI-0p6UjMNuMi4hUMQDTgTIlQqcWMpQ8xGPp6KyTn_MPNn3YJb1YVVLjGxAeq4iHCN_GDIhQ84Ohzqt_NvDLtG4e5q10LjJtl0gYlg6wY56ydcLnjPZleZS495QIWuMngOTvuLu67c87DyFFN_802_g_WKt1qPpFxxTUf3yN2OU9JRawT3yQ2bb5Fbx92u-Ra5067N0Tbl6AH5-RGzpILvaUnnWV3RHGsaF9i3k2JBp7KybIEurAEU8HI0zS_SMMW-PPs0W9ctcbsdexil5T4tyhUxvLAuu-sHBWZMK5x6xwxpLe3D22mR0Mn7z3R3PDqZjk_P9t5QmHuxS2u_glKWFZesnsNTVXW2qCjmwtAA_jOPC7BPG9Mu0j6D06b_yENyfjQ-O5ywrscDi8RALVg4dANEnUBoHQkPnGNgubVBECVuAnYSa25D4QVcJFK5geauVjEm19pYhzyU3iOykRe5fUJoKJMktpFS1rpggXCifOtHQOpUoocD3yF8-XVN1BVAxz4cmekj3dAoDBqFcaVpjMIoh7zu1eZtBZDrFMTSdMwyvRUA2YCPuk5R9Yod_2l5zf-ovkAbNVjRI8eQoS9BXVXGjICgK-CYvnDI9tJ8TQdTlQEhVnyUgv9RfDXmHPKyF8P3xU2lILdFjbcQSOn9geeQx-1g6F_TELioklo6RK4Nk_4HWNt8XZKnF02Nc196GqbST__9WM_IbSCwql0S2yYbi7K2z4EkLsKdBgngqA7dHbL5bjz9dPIL8c1l9w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKkQAJIShXoFAjgdRKNd0kju0gIbSCVlt6PNBD-2ZyODQiSpZkl6p_ih_Er2EmV7sIKC99iaJ4J7HW45lvPBchLyPuKelKn_kgFxk3cAmiAWdChEoldixliNnIe_tidMQ_jr3xAvnR5cJgWGUnE2tBHRcRnpFvOFx4IEcdx383-cawaxR6V7sWGg1b7JizUzDZqrfbH2B9XznO1ubh-xFruwqwSAzUlIWOHSCfB8L3I-GCOA4MNyYIosROYGaxz00o3ICLRCo78DmY5TGmc5rYD3koXXjvNXKdo4sR9o8c9waeDdq69mJz6TIXoNd5xtDGQf9w1ZZrLla6YupvuvB35XBBO85Hbl5QhVt3yZ0Ww9Jhw3T3yILJl8iNvdZLv0RuN2eBtElxuk9-7mJWVvA9Lekkm1U0xxrKBfYJpVhAqqwMm6LKrAUYaFWa5idpmGIfoHWazdOW6N7HnklpuU6L8sIwLFCbTXZGAYnTCk39mCGMpn04PS0SOto-pqubw0_7mweHa28o2Hrs1JivQJRlxSmbTWBW1SybVhRzb2gA38zjAvaDiWkb2Z_Bbd3v5AE5upLVf0gW8yI3jwkNZZLEJlLKGBs4Hm6UZ7wIQKRKfGfgWYR3q6ujtuA69v3IdB9Zh0yhkSm0LXXNFFpZ5HVPNmkqjlxGIDrW0V06LSgADTrxMkLVE7Z4q8FR_0O6gjyqsYJIjiFKX4JZVWk9BINAAab1hEWWO_bVrVisNAxihUkp-B-Hz_e4RV70w7C-6MQKclPM8BUCTQhv4FrkUbMZ-r_JAeyrpC8tIue2Sf8DrKU-P5KnJ3VNdU-6PpjuT_49rRVyc3S4t6t3t_d3npJbAJ5Vcxy3TBan5cw8A4A6DZ_XUoGSz1cthn4BYQ-hKQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9RAFJ4gJMTEGMXbKsqYaAIJI9t2OjM1IQZlCQhsCBfD2zhtp7KxadftroS_6E_w13hOb7BGxRdeNs3OnrbZOZfvzLkR8irivpKeDFgAepFxCx8m6nImRKhU4sRShliNvN8X2yf846l_OkN-NLUwmFbZ6MRSUcd5hGfkay4XPuhR1w3Wkjot4mBz693wG8MJUhhpbcZpmHrMQrxethurizx27cU5uHPF-s4m7P1r193qHX_YZvXEARaJrhqz0HUMyoARQRAJD1S1sdxaY6LESeCt44DbUHiGi0QqxwQcXPYYSz1tHIQ8lB7c9xaZk2D1wRGce9_rHxy2MQ2w5WWMm0uPeQDMLuuJ1o7aL5cdueJhHyym_mYpfzcdV2zndF7nFUO5dY_crREu3ahY8j6ZsdkCmd-vY_gL5E51UkirAqgH5Oce1myZ74MRHaaTgmbYYTnHKaIU20uNCsvGaFBL9QY2lw6ys0E4wClBqzSdph1h8B8nKg1GqzQfXVmGLatrzS4o4HRa4EFAzBBk0zbZnuYJ3d75RJd7G4f93tHxylsKniA7t_YrEKVpfs4mQ3irYpKOC4qVOdTAM7M4B2mxMa3z_lO4LKehPCQnN7L_j8hslmf2CaGhTJLYRkpZ64A8wIXyrR8BxFRJ4Hb9DuHN7uqobseOU0FS3ebdIVNoZArtSF0yhVYd8qYlG1b9SK4jEA3r6KbYFsyDBot5HaFqCWs0VqGs_yFdQh7V2F8kQ0n9YiZFofUGuAsKEK8vOmSxYV9dK81CwyL2n5SC_3H5UgN0yMt2GfYXQ1wms_kEbyHQwfC7Xoc8roSh_ZtcQMZKBrJD5JSYtD_ATuvTK9ngrOy47oNEg2P_9N-vtUTmQSXpvZ3-7jNyG5C1qs7qFsnseDSxzwG9jsMXtVqg5PNNa6Jf7w6sBA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lopinavir+plus+nucleoside+reverse-transcriptase+inhibitors%2C+lopinavir+plus+raltegravir%2C+or+lopinavir+monotherapy+for+second-line+treatment+of+HIV+%28EARNEST%29%3A+144-week+follow-up+results+from+a+randomised+controlled+trial&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Kambugu%2C+Andrew&rft.au=Lugemwa%2C+Abbas&rft.au=Aggrey+Mweemba&rft.au=Abongomera%2C+George&rft.date=2018-01-01&rft.pub=Elsevier+Limited&rft.issn=1473-3099&rft.eissn=1474-4457&rft.volume=18&rft.issue=1&rft.spage=47&rft_id=info:doi/10.1016%2FS1473-3099%2817%2930630-8&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |